《大行報告》花旗:獲COVID-19疫苗相關授權支持雲頂新耀-B(01952.HK)長遠增長
花旗發表研究報告指,雲頂新耀-B(01952.HK)收購mRNA技術,以及未來疫苗的開發潛能,可有助公司長遠增長。雖然未清楚推出產品的時間,但相信消息對股價有正面作用,維持「買入」評級,目標價135元。
該行指,公司與加拿大疫苗開發商Providence Therapeutics達成全面協議,在亞洲市場推進包括新冠疫苗在內的mRNA疫苗及藥品研發。雙方將以合營方式發展。
該股今日收報64元,升5.9%,成交164.4萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.